Sunday, June 22, 2025

Latest

Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug (Pre-IND) meeting request with the US Food and Drug Administration for the use of Bucillamine as a treatment against coronavirus and other infectious diseases.

Revive is currently relying on its previous investigative work with Bucillamine to assist in expediting communications with the FDA, with the goal of being approved for a phase 2 clinical study. The company has previously received phase 2 study approval for Bucillamine for the use of the drug as a treatment for gout and cystinuria.

The company is currently working with its contract research organization, Pharm-Olam, to finalize the protocol to be used in the proposed phase 2 clinical trial. The protocal, as currently developed, proposed a multi-center, randomized, double-blind, placebo-controlled, clinical study. The study will focus on patients with coronavirus currently exhibiting mild to moderate symptoms, with the objective of evaluating the course of the disease in patients receiving Bucillamine as compared to those receiving the placebo.

The study is to also analyze the safety of Bucillamine when administered for up to 14 days, and the time it takes to note clinical improvement in those receiving Bucillamine treatment versus those receiving the placebo.

We are excited to expedite the clinical investigation of Bucillamine in a proposed phase 2 clinical study in the U.S., and we believe our history with the FDA for Bucillamine will provide a compelling case. We will also seek to expand the clinical investigation of Bucillamine in Asian regions, with a particular interest in Japan and South Korea where Bucillamine has been prescribed for treating arthritis for over 30 years. We are in discussion with various contract research organizations (‘CRO’) in these regions.

Michael Frank, Revive’s Chief Executive Officer

Revive Therapeutics last traded at $0.12 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive...

Wednesday, August 18, 2021, 09:23:10 AM

Revive Therapeutics Closes $23.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally...

Friday, February 12, 2021, 11:38:53 AM

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Revive Therapeutics Begins Laying Groundwork For Commercialization Of Bucillamine

Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing...

Thursday, July 15, 2021, 02:27:50 PM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM